Myriad Genetics Announces Enhancements To The GeneSight Test To Personalize Mental Health Medication Treatment Decisions Based On Smoking Status
Portfolio Pulse from Happy Mohamed
Myriad Genetics, Inc. (NASDAQ:MYGN) has announced enhancements to the GeneSight Psychotropic test, a pharmacogenomic test for mental health medications. The GeneSight report will now include information on how a patient's smoking status may impact their body's metabolism of certain medications. This update is based on a comprehensive analysis of peer-reviewed literature and is available immediately for prescribing clinicians.
August 07, 2023 | 8:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Myriad Genetics has enhanced its GeneSight test, which could potentially increase its appeal and usage among clinicians. This could have a positive impact on the company's revenues.
The enhancements to the GeneSight test make it more comprehensive and useful for clinicians, potentially leading to increased usage and revenues for Myriad Genetics.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100